コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 mparative odds = 4.0 for atrial ablation vs. rheumatic fever).
2 e absence of documented Sydenham's chorea or rheumatic fever.
3 ccal throat culture who are at risk of acute rheumatic fever.
4 tein types epidemiologically associated with rheumatic fever.
5 e are likely involved in the pathogenesis of rheumatic fever.
6 complicated pharyngitis, impetigo, and acute rheumatic fever.
7 skin infection and pharyngitis-induced acute rheumatic fever.
8 tis, and correlates of mortality after acute rheumatic fever.
9 a tuberculosis clinic for reasons other than rheumatic fever.
10 f carditis as a major manifestation of acute rheumatic fever.
11 sses and 2 (0.28%) were diagnosed with acute rheumatic fever.
12 tries with the added factors of SH, C'D, and rheumatic fever.
13 logic manifestation of streptococcal-induced rheumatic fever.
14 ly with a decrease in the incidence of acute rheumatic fever.
15 in timely fashion in order to prevent acute rheumatic fever.
16 at which group A streptococcus causes acute rheumatic fever.
17 st-infection sequelae glomerulonephritis and rheumatic fever.
18 of group A streptococcal infection in acute rheumatic fever.
19 ll the Jones Criteria for diagnosis of acute rheumatic fever.
20 . pyogenes, including glomerulonephritis and rheumatic fever.
21 hronic lung or heart disease, and history of rheumatic fever.
22 They had had a total of 20 attacks of acute rheumatic fever.
23 s with the increased frequency of DRB1*16 in rheumatic fever.
24 sence of other major manifestations of acute rheumatic fever.
25 f 182 patients diagnosed with definite acute rheumatic fever, 156 patients were included in the analy
26 atient-years), 19 (0.6%) had recurrent acute rheumatic fever (3.49/1000 patient-years), and 20 (0.7%)
27 djusted odds ratio, 74.6 [CI, 12.5 to 447]), rheumatic fever (adjusted odds ratio, 13.4 [CI, 4.5 to 3
28 e pathogenic mechanisms for developing acute rheumatic fever after group A streptococcal pharyngitis
32 tives of 33 children admitted for "incident" rheumatic fever and 33 control children admitted in a tu
33 nical entity, with a group looking more like rheumatic fever and a group with spondyloarthropathy tra
35 fluoride on group A streptococci that causes rheumatic fever and acute poststreptococcal glomerulonep
36 he current hypotheses of the pathogenesis of rheumatic fever and group A streptococcal autoimmune seq
37 anded expression in nearly all patients with rheumatic fever and is thought to be a trait marker for
38 e intervals between the last attack of acute rheumatic fever and operation ranged from 2 to 8 years.
39 t-infection autoimmune diseases that include rheumatic fever and post-streptococcal glomerulonephriti
41 rategies for the primary prevention of acute rheumatic fever and rheumatic heart disease in children
42 cost-effective option for the management of rheumatic fever and rheumatic heart disease in India, an
43 e strategy for the prevention and control of rheumatic fever and rheumatic heart disease in India.
44 mbinations for the prevention and control of rheumatic fever and rheumatic heart disease in India.
45 rmance in screening for and diagnosing acute rheumatic fever and rheumatic heart disease needs furthe
46 ecisions by efficient resource allocation on rheumatic fever and rheumatic heart disease prevention a
47 702 patients enrolled in a population-based rheumatic fever and rheumatic heart disease registry in
49 dies on the screening and diagnosis of acute rheumatic fever and rheumatic heart disease using handhe
54 lly respiratory infections at older ages and rheumatic fever and syphilis at younger ages, predicted
55 ints and cardiac valves in disorders such as rheumatic fever and systemic lupus erythematosus remain
56 d aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in
58 ocumented GAS infections (pharyngitis, acute rheumatic fever, and severe invasive disease) also had s
61 gated adverse outcomes for people with acute rheumatic fever (ARF) and rheumatic heart disease (RHD)
63 as serious autoimmune sequelae such as acute rheumatic fever (ARF) and subsequent rheumatic heart dis
65 Archived sera (collected in 1946) from acute rheumatic fever (ARF) and untreated scarlet fever and/or
70 rom group A streptococcus, episodes of acute rheumatic fever (ARF), cases of RHD, heart failure, and
71 otein is an epidemiological marker for acute rheumatic fever (ARF)-associated serotypes of group A st
72 es, Kawasaki disease has now surpassed acute rheumatic fever as the leading cause of acquired heart d
73 ted motifs were present in only 15.1% of the rheumatic fever-associated emm types and only 24.8% of c
75 med to provide a comprehensive list of acute rheumatic fever-associated GAS isolates and assess the p
78 was used to analyze the protein diversity of rheumatic fever-associated strains in a phylogenetic tre
79 utoimmunity: beta-hemolytic streptococci and rheumatic fever; B3 Coxsackieviruses and myocarditis; Tr
80 presence of an "inherited predisposition" to rheumatic fever because the disease was more prevalent a
82 f 16 subjects 7-21 years old who had not had rheumatic fever but who had possible PANDAS anorexia ner
83 tional guidelines for the diagnosis of acute rheumatic fever by defining high-risk populations, recog
84 was considered part of the spectrum of acute rheumatic fever by some, whereas others stressed the dif
86 have the diagnostic Jones criteria for acute rheumatic fever changed, but substantial advances have b
87 Rheumatic heart disease (RHD), a sequela of rheumatic fever characterized by permanent heart valve d
88 fections, myringotomy, measles, hepatitis A, rheumatic fever, common colds, rubella and chronic sinus
89 ft atrial calcification was 19.0 vs. 4.8 for rheumatic fever (comparative odds = 4.0 for atrial ablat
90 calcifications cohort presented a history of rheumatic fever compared with zero in the control cohort
93 hazard ratio 4.4 [95% CI 1.7-11.2]) at acute rheumatic fever diagnosis were associated with increased
94 lready had chronic carditis at initial acute rheumatic fever diagnosis, suggesting previous undiagnos
96 Cardiovascular Disease in the Young and its Rheumatic Fever, Endocarditis, and Kawasaki Disease Comm
97 ation under the auspices of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Cou
98 ans to diagnose cardiac involvement in acute rheumatic fever, even when overt clinical findings are n
101 that serum samples from patients with acute rheumatic fever have higher levels of antibodies that re
102 a recent increase in the incidence of acute rheumatic fever in North America, rheumatic heart diseas
103 storic Jones criteria used to diagnose acute rheumatic fever in the context of the current epidemiolo
104 ghlight the large burden of undetected acute rheumatic fever in these settings and the need for impro
105 t-streptococcal glomerulonephritis and acute rheumatic fever indicated that FBP54 is expressed in viv
106 ive soft tissue infections, pharyngitis, and rheumatic fever indicated that Slr is produced in vivo.
107 ive soft tissue infections, pharyngitis, and rheumatic fever indicated that these four proteins are e
111 Sydenham's chorea, a major manifestation of rheumatic fever, may provide a medical model for obsessi
113 psoriasis (HR, 1.66; 95% CI, 1.02-2.70), and rheumatic fever or rheumatic carditis (HR, 1.75; 95% CI,
118 in diagnosing rheumatic heart disease, acute rheumatic fever, or carditis with acute rheumatic fever
120 ated death, and 17 (11%) had recurrent acute rheumatic fever over a median of 4.3 (IQR 3.0-4.8) years
121 icant knowledge gaps in the understanding of rheumatic fever pathogenesis and suggest that a GAS vacc
123 of population-specific differences in acute rheumatic fever presentation and changes in presentation
124 t of GAS pharyngitis are cornerstones of the Rheumatic Fever Prevention Programme, but these are hind
125 cute rheumatic fever, or carditis with acute rheumatic fever (primary outcomes) were extracted from p
127 l on the hereditary versus social origins of rheumatic fever, Read, Ciocco, and Taussig, from Johns H
128 aimed to describe 3-5 year mortality, acute rheumatic fever recurrence, changes in carditis, and cor
129 We calculated rates of mortality and acute rheumatic fever recurrence, tabulated changes in carditi
136 Several challenges are unique to the acute rheumatic fever/RHD continuum and contribute to its pers
137 lementation of evidence-based strategies for rheumatic fever/RHD prevention, (3) access to essential
139 ewardship, particularly in the management of rheumatic fever, rheumatic heart disease, bacterial endo
140 of 13 KS sera, as compared with 5 of 8 acute rheumatic fever sera, contained Ab titers to human cardi
141 a different pattern of reactivity than acute rheumatic fever sera, further supporting the association
142 homologue in certain diseases such as acute rheumatic fever, suggest that SOK plays an important rol
143 l was to determine whether a trait marker of rheumatic fever susceptibility (labeled D8/17) could ide
144 hors' goal was to determine whether D8/17, a rheumatic fever susceptibility trait marker, identifies
145 mphocyte antigen with expanded expression in rheumatic fever, Sydenham's chorea, and subgroups of obs
146 pathogenesis may be more similar to that of rheumatic fever than to that of ReA associated with ente
148 othesis is proven in a few illnesses such as rheumatic fever, there is no definitive evidence of an i
150 years who were diagnosed with definite acute rheumatic fever using the modified 2015 Jones criteria f
151 -specific antibody responses associated with rheumatic fever were identified from 1 January 1944 to 3
152 e revised Jones criteria were used to define rheumatic fever with a maximum period of 4 weeks between